We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drugmakers Weigh in on FDA’s Biosimilar Insulin Guidance
Drugmakers Weigh in on FDA’s Biosimilar Insulin Guidance
In comments to the FDA, drugmakers called on the agency to clarify in its draft guidance for biosimilar and interchangeable insulin products that the agency will still hold applicants to the current licensing standards.